Biotech Catalysts This Week: FDA Decisions, Readouts & Earnings (Aug 30–Sep 6, 2026)
Here’s what’s on the biotech calendar for August 30–September 6: 0 FDA decision dates, 15 trial catalysts, and 0 earnings reports from tracked companies.
🧪 Trial Catalysts & Milestones
- APGE, 2026-09-01: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Immunogenicity…
- OSTX, 2026-09-01: Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery Registry
- ORIC, 2026-09-01: Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration Registry
- ARVN, 2026-09-01: TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C) Registry
- BHVN, 2026-09-01: Taldefgrobep Alfa in Adults With Overweight and Obesity Registry
- BHVN, 2026-09-01: Study of BHV-1300 in Graves' Disease Registry
- GILD, 2026-09-01: Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis Registry
📡 Run-up Radar Highlights
Stocks entering the pre-catalyst window with the strongest setups (full radar is a Premium feature):
- NUVL: NDA in 19 days, score 61/100
- CYTK: Phase 2, Recruiting in 2 days, score 59/100
- SNDX: Phase 2, Active Trial in 2 days, score 50/100
📈 Last Week’s Biggest Gainers
- BHVN +17.87% (volume 5.5x average)
Track your tickers on the BioRadar dashboard →
This digest is for informational purposes only and is not investment advice. Always do your own research.